Discover how AFM13, a tetravalent bispecific antibody, is transforming treatment for relapsed/refractory Hodgkin lymphoma by harnessing NK cells.
Explore how monoclonal antibodies are transforming cancer treatment through targeted therapy, with the latest breakthroughs in 2025.
Exploring IL-2's evolution from toxic cancer drug to precision weapon against acute myeloid leukemia relapse during remission.